Extract from the Register of European Patents

EP About this file: EP3212629

EP3212629 - SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW ANTICANCER AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.08.2019
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  21.09.2018
FormerGrant of patent is intended
Status updated on  08.08.2018
FormerRequest for examination was made
Status updated on  06.07.2018
FormerGrant of patent is intended
Status updated on  07.05.2018
FormerRequest for examination was made
Status updated on  04.08.2017
FormerThe international publication has been made
Status updated on  26.05.2017
Most recent event   Tooltip30.08.2019No opposition filed within time limitpublished on 02.10.2019  [2019/40]
Applicant(s)For all designated states
Genoscience Pharma SAS
10, rue d'Iena
13006 Marseille / FR
[2017/36]
Inventor(s)01 / BASSISSI, Firas
19, rue Pierre Laurent
Appartement 104
13006 Marseille / FR
02 / BERET, Antoine
54, Chemin de Morgiou
13009 Marseille / FR
03 / BRUN, Sonia
Résidence les Fleurs
Appartement B201
115, rue Isaac Newton
13100 Aix-en-Provence / FR
04 / COURCAMBECK, Jérôme
50, Boulevard du Vaisseau
Les Hauts de Mazargues D5
13009 Marseille / FR
05 / DUBRAY, Clarisse
Le Belvédère
Appartement B305
17, rue du Docteur Alfred Corlay
44800 Saint-Herblain / FR
06 / NICOLAS, Gregory
8, rue des Saules
35510 Cesson Sevigne / FR
07 / HALFON, Philippe
6, Allée du Château
Parc Marveyre
13008 Marseille / FR
 [2017/41]
Former [2017/36]01 / BASSISSI, Firas
19, rue Pierre Laurent
Appartement 104
13006 Marseille / FR
02 / BERET, Antoine
54, Chemin de Morgiou
13009 Marseille / FR
03 / BRUN, Sonia
160, rue Edmond Haley
Résidence Le Clos de Médicis
Appartement B205
La Duranne
13100 Aix-en-Provence / FR
04 / COURCAMBECK, Jérôme
50, Boulevard du Vaisseau
Les Hauts de Mazargues D5
13009 Marseille / FR
05 / DUBRAY, Clarisse
51, Avenue du Pigonnet
Résidence Jean Giono
13090 Aix-en-Provence / FR
06 / NICOLAS, Gregory
126, rue Augustin Aubert
Entrée B
13009 Marseille / FR
07 / HALFON, Philippe
6, Allée du Château
Parc Marveyre
13008 Marseille / FR
Representative(s)Santarelli
7, rue de la République
13001 Marseille / FR
[2017/36]
Application number, filing date15837091.626.10.2015
[2017/36]
WO2015IB02438
Priority number, dateUS201462073325P31.10.2014         Original published format: US 201462073325 P
[2017/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016067112
Date:06.05.2016
Language:EN
[2016/18]
Type: A1 Application with search report 
No.:EP3212629
Date:06.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 06.05.2016 takes the place of the publication of the European patent application.
[2017/36]
Type: B1 Patent specification 
No.:EP3212629
Date:24.10.2018
Language:EN
[2018/43]
Search report(s)International search report - published on:EP06.05.2016
ClassificationIPC:C07D401/04, A61K31/47, A61P35/00
[2017/36]
CPC:
C07D401/04 (EP,CN,IL,US); A61K31/4545 (IL,US); A61K31/506 (IL,US);
A61K9/1273 (IL,US); A61K9/14 (IL,US); A61P1/04 (EP);
A61P1/16 (EP); A61P1/18 (EP); A61P11/00 (EP);
A61P11/02 (EP); A61P11/04 (EP); A61P13/08 (EP);
A61P13/12 (EP); A61P15/00 (EP); A61P17/00 (EP);
A61P25/00 (EP); A61P35/00 (EP,US); A61P35/02 (EP);
A61P35/04 (EP); A61P43/00 (EP); C07D401/14 (CN,IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/36]
Extension statesBANot yet paid
MENot yet paid
Validation statesMA11.05.2017
TitleGerman:SUBSTITUIERTE 2,4 DIAMINO-CHINOLIN ALS NEUE ANTIKREBSMITTEL[2017/36]
English:SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW ANTICANCER AGENTS[2017/36]
French:2,4-DIAMINO-QUINOLÉINE SUBSTITUÉE SERVANT DE NOUVEAUX AGENTS ANTICANCÉREUX[2017/36]
Entry into regional phase11.05.2017National basic fee paid 
11.05.2017Designation fee(s) paid 
11.05.2017Examination fee paid 
Examination procedure11.05.2017Examination requested  [2017/36]
11.05.2017Date on which the examining division has become responsible
10.11.2017Amendment by applicant (claims and/or description)
08.05.2018Communication of intention to grant the patent
27.06.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
09.08.2018Communication of intention to grant the patent
12.09.2018Fee for grant paid
12.09.2018Fee for publishing/printing paid
12.09.2018Receipt of the translation of the claim(s)
Opposition(s)25.07.2019No opposition filed within time limit [2019/40]
Fees paidRenewal fee
27.09.2017Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL24.10.2018
SM24.10.2018
[2019/37]
Former [2019/26]AL24.10.2018
Cited inby applicant  GREVE, B. ET AL., CYTOMETRY A, 2012, pages 284 - 293
   LIU, S. ET AL., PLOS ONE, 2013, pages E81050
   RAN, D. ET AL., EXP. HEMATOL., 2009, pages 1423 - 1434
   CHEUNG, A. M., LEUKEMIA, 2007, pages 1423 - 1430
   PEARCE, D. J. ET AL., STEM CELLS, 2005, pages 752 - 760
   "Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2014, WOLTERS KLUWER HEALTH
   "Remington: The Science and Pratice of Pharmacy", 2012, PHARMACEUTICAL PRESS
   "Prodrugs: Challenges and Rewards", 2007, SPRINGER
   "Prodrugs and Targeted Delivery: Towards Better ADME Properties", 2011, WILEY-VCH
   STORMS, R. W.; TRUJILLO, A. P.; SPRINGER, J. B.; SHAH, L.; COLVIN, O. M.; LUDEMAN, S. M.; SMITH, C.: "Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 96, no. 16, 1999, pages 9118 - 9123
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.